OBJECTIVE—Evidence links the hypothalamic fatty acid synthase (FAS) pathway to the regulation of food intake and body weight. This includes pharmacological inhibitors that potently reduce feeding and body weight. The mammalian target of rapamycin (mTOR) is an intracellular fuel sensor whose activity in the hypothalamus is also linked to the regulation of energy balance. The purpose of these experiments was to determine whether hypothalamic mTOR complex 1 (mTORC1) signaling is involved in mediating the effects of FAS inhibitors.

RESEARCH DESIGN AND METHODS—We measured the hypothalamic phosphorylation of two downstream targets of mTORC1, S6 kinase 1 (S6K1) and S6 ribosomal protein (S6), after administration of the FAS inhibitors C75 and cerulenin in rats. We evaluated food intake in response to FAS inhibitors in rats pretreated with the mTOR inhibitor rapamycin and in mice lacking functional S6K1 (S6K1−/−). Food intake and phosphorylation of S6K1 and S6 were also determined after C75 injection in rats maintained on a ketogenic diet.

RESULTS—C75 and cerulenin increased phosphorylation of S6K1 and S6, and their anorexic action was reduced in rapamycin-treated rats and in S6K1−/− mice. Consistent with our previous findings, C75 was ineffective at reducing caloric intake in ketotic rats. Under ketosis, C75 was also less efficient at stimulating mTORC1 signaling.

CONCLUSIONS—These findings collectively indicate an important interaction between the FAS and mTORC1 pathways in the central nervous system for regulating energy balance, possibly via modulation of neuronal glucose utilization. Diabetes 57: 3231–3238, 2008

Energy balance is achieved when caloric intake is matched to expenditure. A complex neuroendocrine system underlies this process and regulates energy homeostasis in mammals. In addition to sensing hormonal signals of stored fuels, such as leptin (1), specific populations of neurons in the central nervous system (CNS), and particularly within the hypothalamus, have the ability to sense locally available nutrients, including glucose (2), fatty acids (3), and amino acids (4,5).

Recent evidence has highlighted the role of intracellular fuel sensing in the regulation of energy balance (6). In particular, the biochemical pathway underlying fatty acid metabolism has been involved in the regulation of both feeding and glucose homeostasis (6–10). Fatty acid synthase (FAS) catalyzes the condensation of malonyl-CoA and acetyl-CoA to generate long-chain fatty acids (LCFAs). Acetyl-CoA carboxylase (ACC) and FAS are expressed in the hypothalamus (7), where malonyl-CoA (11) and LCFA-CoA levels (8) decrease during fasting and increase after refeeding. Studies using FAS inhibitors and other pharmacological or genetic tools that modify the activity of different enzymes regulating fatty acid metabolism support a role for this pathway in the regulation of feeding (9,12–15).

Peripheral administration of the natural FAS inhibitor cerulenin (2,3-epoxy-4-oxo-6-dodecadienoylamide) or the synthetic inhibitor C75 (trans-4-carboxy-5-octyl-3-methyl-enecarbonylactone) causes profound dose-dependent anorexia and weight loss in several rodent models (12,13,15,16). Reduced food intake is also observed with central administration of much lower doses of C75, suggesting that the brain is the key site of action (12). Increased hypothalamic malonyl-CoA is necessary for the anorexic and weight-reducing effects of FAS inhibitors (9,15,17). Interestingly, the ability of leptin to reduce food intake depends on increased hypothalamic malonyl-CoA (8) and possibly palmitoyl-CoA (18), which are achieved through the concomitant inhibition of AMP-activated protein kinase (AMPK) and activation of ACC (18). Therefore, the hypothalamic fatty acid synthesis pathway appears to process different fuel signals and convert them to efferent outputs that prevent further consumption of nutrients.

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that controls critical aspects of cell growth (19). mTOR is a component of at least two multiprotein complexes: mTOR complex 1 (mTORC1), which includes raptor, and mTOR complex 2 (mTORC2), which includes rictor. Whereas mTORC2 regulates phosphorylation of Akt, mTORC1 modulates the activity of S6 kinase 1 (S6K1) and 4E binding protein 1 (20). Notably, the phosphorylation of S6K1 at Thr389 is one of the markers commonly used to evaluate mTORC1 activity in vivo (21). Insulin, IGF, amino acids, and glucose all activate intracellular cascades that lead to activation of mTORC1 (22). We reported that the anorexic action of central leptin and leucine are both dependent on the activation of mTORC1 signaling in the hypothalamus (4). Given the ability of mTORC1 to sense and integrate fuel signals, and the role it plays in controlling food intake (4), we hypothesized that mTORC1 signaling is involved in monitoring the biochemical changes induced by the modulation of hypothalamic fatty acid metabolism.
RESEARCH DESIGN AND METHODS

Animals. Adult male Long-Evans rats, S6K1−/− mice, and their wild-type littermates (23) were used. Mice were 8–11 weeks old in the cerulein study and 7 months old in the C75 study. All animals were housed individually and maintained on a 12:12-h light-dark cycle, standard lab chow (Harlan-Teklad, Indianapolis, IN), and water. All animal procedures were approved by the institutional animal care and use committee of the University of Cincinnati. Rats were implanted with intracerebroventricular (icv) cannulas as previously described (24) and allowed to recover for a minimum of 7 days. Cannula placement was confirmed by consuming >5 ml water after 10 mg angiotensin II icv.

Drugs. C75 (Calbiochem; EMD Bioscience, La Jolla, CA) was dissolved in RPMI (Gibco, Carlsbad, CA). Cerulein (Sigma-Aldrich, St. Louis, MO) was first dissolved in DMSO followed by RPMI, to a final concentration of 25% DMSO. Rapamycin (Calbiochem, EMD Bioscience) was dissolved in DMSO. All vehicles served as controls.

Ketogenic diet. Rats were placed on a ketogenic diet (80.7% lipid, 14.3% protein, and 5.6% carbohydrates; Dyet 100059; Dyets, Bethlehem, PA) for 4 weeks (13). Blood β-hydroxybutyrate concentration was measured using the KetroSite test (Stanbio Laboratory, Boerne, TX).

Leucine measurement. Plasma samples were deproteinized with sulfosalicylic acid and analyzed using an automated Hitachi L8300 Amino Acid Analyzer.

Western blot. A wedge of mediobasal hypothalamus was dissected using landmarks the mammillary bodies caudally, the optic chiasm rostrally, the optic tract laterally, and the apex of the third ventricle. Tissues were homogenized in radioimmunoprecipitation assay buffer with addition of phosphatase and protease inhibitors (Santa Cruz Biotechnology). Samples (70 μg) were loaded on either a 9–13% (experiment 1) or a 10% (experiments 3 and 4) SDS-polyacrylamide gel (Bio-Rad). Proteins were separated by electrophoresis and transferred to nitrocellulose membranes. Membranes were blocked as previously described (4) before overnight incubation at 4°C with either phosphorylated S6K1 (pS6K1) at Thr 389 (1:500; Cell Signaling Technology, Beverly, MA) or phosphorylated S6 (pS6) at Ser 240/244 (1:500; Cell Signaling Technology). After washing in Tris-buffered saline with Tween (TBST), the membranes were incubated for 1 h at room temperature with secondary antibody conjugated with horseradish peroxidase (goat anti-rabbit; 1:2,000; Cell Signaling Technology). After washes in TBST, immunopositive bands were visualized by chemiluminescence (Lumiglo reagent and peroxide kit; Cell Signaling Technology) using exposure to radiographic films (Denville Scientific, South Plainfield, NJ). After protein detection, membranes were stripped for 15 min at 55°C with a solution containing 62.5 mmol/l Tris-HCl, 100 mmol/l 2-mercaptoethanol, and 2% SDS before 2-h blocking in TBST with 5% skim milk powder at room temperature and rebotted with either rabbit anti-pS6K1 (Cell Signaling Technology, 1:250) or rabbit anti-S6 (1:500; Cell Signaling Technology). Density was determined by National Institutes of Health program Scion image.

Experimental design

Experiment 1: effect of C75 on hypothalamic mTORC1 signaling. One hour before dark, rats were injected with C75 (30 μg in 2 μl icv) or vehicle and killed 30 min, 1 h, or 6 h later. Brains were removed, immediately frozen in isopentane, and stored at −80°C until Western blot analysis.

Experiment 2: effect of rapamycin on C75-induced anorexia in rats. Three hours before dark, rats were injected with either DMSO or rapamycin (25 μg in 1 μl icv) followed by RPMI or C75 (50 μg in 3 μl icv) 2 h later. Food was weighed at 1, 4, 8, and 24 h. Body weight was measured at 24 h. As previously reported (15), we found that some CNS active compounds, including leptin and C75, are less effective when animals are pretreated with DMSO. In these conditions, the dose of C75 had to be raised to 50 μg to reach the same depth of anorexia as that observed with 30 μg.

Experiment 3: anorexic actions of C75 and cerulein in S6K1−/− mice. One hour before dark, mice were injected intraperitoneally with C75 (20 mg/kg body wt), cerulein (160 mg/kg body wt), or their respective vehicles; and food was weighed at 1, 4, 10, and 24 h. Body weight was measured at 24 h. The experiments used a within-subjects design with treatment order counterbalanced and 1 week between each treatment.

Experiment 4: effect of cerulenin on hypothalamic mTORC1 signaling. Rats were injected intracerebroventricularly with cerulenin (90 μg in 2 μl) and killed as in experiment 1.

Experiment 5: effect of the ketogenic diet on C75-induced anorexia. Rats were divided into two groups (sucrose or saccharin). All rats had ad libitum access to a ketogenic diet, water, and a sucrose or saccharin solution (13). Four weeks later, rats were fasted for 24 h, and ketosis was confirmed by a significant elevation of blood β-hydroxybutyrate in rats that had access to saccharin versus sucrose. Three days later, rats were fasted overnight and given RPMI or C75 (30 μg in 2 μl icv) 1 h before lights off. Food and bottles of sucrose or saccharin were returned and weighed at 4 and 24 h.

RESULTS

C75 increases hypothalamic mTORC1 signaling. C75 had no effect on the phosphorylation of either S6K1 or S6K1/S6K1: RPMI, 100.00 ± 8.36% vs. C75, 86.49 ± 11.68% of RPMI; P = 0.365) or S6 (pS6/S6: RPMI, 100 ± 18.36% vs. C75, 105.59 ± 14.45% of RPMI; P = 0.816) 30 min after injection. At 1 h, C75 increased the phosphorylation of S6 (Fig. 1A and B), and at 6 h, this was accompanied by a significant elevation of pS6K (Fig. 1C and D).

mTORC1 signaling mediates the anorexic action of C75. We have found that refeeding activates hypothalamic mTORC1 signaling, whereas pharmacological inhibition of CNS mTOR increases food intake in rats (4). Given that C75 increased hypothalamic pS6K1 and pS6, we evaluated whether C75-induced anorexia depends on activation of the mTORC1 signaling by using the potent and selective mTOR inhibitor rapamycin (25). There was a main effect of the second drug treatment on food intake (F(1, 46) = 29.03, P < 0.001). Within the 1st h after injection, C75 reduced food intake (P < 0.01), and this effect persisted for the following 24 h (Fig. 2A and B). There was a main effect of the first drug treatment on food intake (F(1, 46) = 5.53, P < 0.05). The dose of rapamycin used decreased feeding in the 1st h (P < 0.01; Fig. 2A), which was surprising given that we had never observed an effect of this dose in any prior studies (Appendix 1, which is available in an online appendix at http://dx.doi.org/10.2337/db07-1690) (4). Nonetheless, pretreatment with rapamycin blocked C75-induced anorexia by 4 h (P < 0.05; Fig. 2A), and the inhibition persisted at 24 h (Fig. 2A and B). There was an interaction between the first and second drug treatments on food intake at 8 h (F(1, 46) = 4.16, P < 0.05). There were main effects of the first (F(1, 46) = 7.63, P < 0.01) and second drug treatments on body weight (F(1, 46) = 10.57, P < 0.01). Rapamycin prevented the weight loss effect of C75 over 24 h (P < 0.05; Fig. 2C). The interaction between the two drug treatments approached significance (F(1, 46) = 4.03, P = 0.05).

To assess the role of the mTORC1 pathway in mediating the potent anorexic effects of FAS inhibitors, we used S6K1−/− and their wild-type littermates. As previously reported (26), S6K1−/− mice had lower body weights than wild-type mice (wild type, 29.36 ± 1.30 vs. S6K1−/−, 25.60 ± 0.78 g; P < 0.05). However, their cumulative 24-h food intake was similar to that of controls, whether expressed as total intake (Fig. 2E) or intake per kilogram body weight (wild type/RPMI, 139.68 ± 26.99 vs. S6K1−/−/RPMI, 156.38 ± 15.52 g/kg body wt; P = 0.603). There was a main effect of drug on feeding (F(1, 10) = 30.07, P < 0.001). C75 significantly decreased food intake in both genotypes in the 1st h (P < 0.01; Fig. 2D). The suppression lasted at least 24 h in wild-type mice (P < 0.01; Fig. 2D and E). However, the response of S6K1−/− mice was signifi-
observation that two different FAS inhibitors modulate hypothalamic mTORC1 and require mTORC1 signaling for their anorexic action makes a strong case for a link between mTORC1 and FAS in the regulation of feeding.

The actions of C75 on hypothalamic mTORC1 signaling are blunted in ketotic rats. We had previously hypothesized that a key signal leading to C75-induced anorexia is derived, at least in part, from its ability to increase CNS glucose utilization, and we demonstrated that C75 does not reduce food intake under ketosis (13). Here, we explored the possibility that this is due to inability to modulate CNS mTORC1 signaling. Blood β-hydroxybutyrate was significantly elevated in rats given access to saccharin versus sucrose (P < 0.001; Fig. 4A). There was a main effect of drug on food intake at 4 h (F(1,29) = 12.74, P < 0.01) and at 24 h (F(1,29) = 9.33, P < 0.01). Consistent with its effect on chow, C75 reduced caloric intake in rats whose ketosis was prevented by access to sucrose (P < 0.01), and this effect lasted for 24 h. However, the caloric-reducing effect of C75 was blunted in ketotic rats receiving saccharin at 4 (data not shown) and 24 h (Fig. 4B) and was nearly statistically different from that of rats in the sucrose group (P = 0.059; Fig. 4B). These effects were accompanied by reduced hypothalamic mTORC1 signaling in ketotic rats compared with sucrose rats. There was a main effect of drug on pS6K1 (F(1,27) = 5.56, P < 0.05) and pS6 (F(1,26) = 27.19, P < 0.001). The effect of diet (F(1,26) = 3.89, P = 0.059) and the interaction between drug and diet (F(1,26) = 3.92, P = 0.058) nearly reached statistical significance for pS6. C75 was less efficient at increasing pS6 in ketotic rats versus sucrose rats (P < 0.05; Fig. 4D), and it increased pS6K1 only in sucrose rats (P < 0.01) (sucrose-C75 vs. saccharin-C75, P < 0.05; Fig. 4C). Thus, the anorexic action of C75 appears to depend on the rate of neuronal glucose uptake.
and/or utilization. Moreover, this rate could also affect the ability of C75 to modulate mTORC1 signaling. Ketosis is known to induce profound metabolic changes (27), so we compared sucrose- versus saccharin-treated rats on the same gel. Ketosis had no significant effect on the basal phosphorylation of S6K1 but caused a nonsignificant increase in S6 phosphorylation (Appendix 2, which is available in the online appendix). Rats fed a ketogenic diet have increased leucine levels in the cerebral cortex (28). Given the important role of leucine in regulating mTOR (29,30), we determined whether the ketogenic diet changes plasma leucine levels. However, we did not find any difference in circulating leucine between the two groups (Fig. 4E).

**DISCUSSION**

Modulation of the FAS pathway represents a therapeutic strategy to produce weight loss and points to the important role of CNS metabolic pathways in regulating energy balance (6,31). Our previous work has demonstrated that activation of mTORC1 signaling in the hypothalamus reduces food intake (4). This led us to hypothesize that the ability of FAS inhibitors to modulate hypothalamic

![Graphs and diagrams](https://example.com/figure2.png)

**FIG. 2.** mTORC1 signaling contributes to the anorexic effect of C75. Rapamycin (RAPA; 25 μg in 1 μl DMSO icv) prevents the effects of C75 (50 μg in 3 μl RPMI icv) on food intake (A and B) and on body weight change (C). Data are the mean of two separate experiments. Means ± SE of 9–15 rats in each treatment group. **P < 0.01; ***P < 0.001 vs. DMSO/RPMI-treated rats; #P < 0.05 vs. RAPA/C75-treated rats. D and E: The anorexic effect of C75 (20 mg/kg, in 1 ml/100 g body wt RPMI ip) is significantly reduced in S6K1−/− mice. F: Body weight change over 24 h in mice injected with RPMI or C75. Means ± SE of six mice in each treatment group. Food intake is expressed as the noncumulative amount consumed during different time intervals (A and D) and the cumulative amount eaten during 24 h (B and E). *P < 0.05; **P < 0.01; ***P < 0.001 vs. wild-type (RPMI)-treated mice; #P < 0.05 vs. S6K1−/− (C75)-treated mice.
mTORC1 signaling is an important mechanism by which they cause anorexia.

Here, we report that central administration of C75 or cerulenin increases phosphorylation of hypothalamic S6K1 and S6. Furthermore, the ability of these compounds to modulate feeding depended on the activation of CNS mTORC1 signaling. In fact, intracerebroventricular rapamycin dampened the ability of C75 to reduce both feeding and body weight (4). We were surprised to observe an effect of rapamycin to reduce feeding in the 1st h after injection, given that we had not seen an effect of this dose in several prior studies (Appendix 1) (4). Nonetheless, it is important to point out that this effect on food intake is short-lived, with no effect observed beyond 1 h. Importantly, rapamycin actually resulted in an increase in intake in the presence of C75, which is incompatible with a major effect of rapamycin to reduce food intake.

Although rapamycin is quite specific in its effect on mTORC1 signaling (4), pharmacological inhibitors can have drawbacks that limit the interpretation of experimental results. Hence, we further tested our hypothesis in mice lacking S6K1, a key component of the mTORC1 pathway. C75 or cerulenin reduced both food intake and body weight in wild-type mice, as reported before (17,32). However, this effect was significantly reduced in S6K1−/− mice. Interestingly, the data arising from both the pharmacological and genetic studies indicate that the activity of the mTORC1 pathway critically contributes to the anorexic effects of FAS inhibitors 4 h after drug injection. The time course observed in S6K1−/− mice is a remarkable match for the observation made in rats that activation of mTORC1 remains elevated 6 h after either C75 or cerulenin. Such data underscore the importance of the mTORC1 signaling as one component...
of a cascade that is essential to the anorexic effects of FAS inhibitors.

One proposed mechanism by which FAS inhibitors suppress food ingestion is by increasing CNS glucose utilization (13). Glucose metabolism is a biochemical index of nutrient status that plays a key role in the control of feeding. Quantitative and temporal changes in glucose concentration are closely monitored and integrated by specific subpopulations of “glucosensing” neurons in the CNS that are crucial to the regulation of feeding (6). A key finding to support the involvement of increased glucose use in mediating the effect of FAS inhibition is that rats on a very low carbohydrate diet, which forces them to produce ketone bodies that neurons use in preference to glucose (33), do not reduce their food intake in response to C75 (13). In accordance with those previous results, we observed that rats maintained on a ketogenic diet but given sucrose to prevent ketosis responded to C75. In contrast, rats maintained on the ketogenic diet but given saccharin did not significantly reduce their food intake after C75. C75 increased S6 phosphorylation in rats on the ketogenic diet supplemented with sucrose, but this effect is blunted in those on the same diet supplemented with saccharin. This effect is consistent with what has been
observed under chow diet. It remains unknown how C75 increases the phosphorylation of S6K1 1 h after injection under a ketogenic diet supplemented with sucrose, whereas this phenomenon happens only at 6 h under a chow diet. This is an issue that we tested several times with multiple time points. In several studies, there was a strong trend for increased pS6K1 at 1 h, but this effect was not consistent across experiments, unlike the reliable effect to increase pS6. There could be a number of possibilities to explain why the time course of C75-induced phosphorylation of S6K1 differs between the two diets. The ketogenic diet induces a wide range of metabolic effects in addition to reducing glucose availability (27). These differences provide an important rationale for why we used the ketogenic diet supplemented with sucrose instead of a normal chow diet as the control for experiment 4. Nonetheless, these findings not only point to the permissive role played by neuronal glucose metabolism in the FAS inhibitors-induced anorexia, but they also highlight a mechanism through which the inhibition of FAS leads to the modulation of the mTORC1 signaling.

Kim et al. (17) ascribed the anorexic action of C75 to its ability to inhibit hypothalamic AMPK. Like mTOR, AMPK is a fuel sensor that plays a critical role in integrating signals of energy status in the hypothalamus and regulating food intake. However, in contrast to mTOR, hypothalamic AMPK is activated during negative energy balance, in which case it stimulates feeding (34). The relationship between these two fuel sensors is rather complex and appears to be bidirectional (35,36). Given the highly regulated crosstalk between mTOR and AMPK, the current experiments cannot rule out whether the effects of C75 on the mTORC1 pathway are directly mediated or occur as a result of inhibition of hypothalamic AMPK. Nonetheless, the data of Kim et al. (17) suggest that AMPK activity is involved primarily in the short-term actions of C75 because AMPK activators inhibit the effect of C75 specifically during the 1st h after drug administration, whereas our data suggest that mTORC1 signaling might be critical at later time points.

In conclusion, we provide evidence that links the FAS pathway to the mTORC1 signaling cascade in the CNS and, although the current experimental design does not allow us to conclude whether the ability of FAS inhibition to reduce food intake is due exclusively to actions in the hypothalamus, the literature would argue that it is the case. Several studies have attributed the hypophagic action of FAS inhibition to direct effects on hypothalamic neurons (31,37–40), and this model has been further supported in the recent study of Chakravarthy et al. (40). This group demonstrated that genetic inactivation of FAS in the hypothalamus and β-cells results in anorexia entirely due to inactivation of the enzyme in the hypothalamus. Moreover, nutritional regulation of mTORC1 signaling occurs specifically in the hypothalamus (4). Taking into account that leptin also activates mTORC1 in the hypothalamus (4) and reduces food intake through actions on CNS fatty acid metabolism (18), this suggests that mTORC1 is an important integrator of multiple signals in the CNS. mTORC1 activity can be found in both agouti-related protein- and proopiomelanocortin-producing neurons in the arcuate nucleus (4), and, thus, increased mTORC1 activity in the CNS may contribute to the similar effects of C75 and leptin on both food intake and hypothalamic gene expression (15,17,41). The current data connect two separate metabolic pathways that have been independently implicated in the CNS regulation of energy balance, thus providing new knowledge on the relationship among key signaling pathways able to affect feeding behavior. Identifying the specific metabolic signals that are integrated by energy-sensing neurons is a crucial scientific question that could give important insights into potential etiologies and therapies for obesity and other metabolic disorders.

ACKNOWLEDGMENTS

R.J.S. and C.S.W. have received National Institutes of Health Grants DK-17844, DK-54890, and DK-056863 and funds from the DoD Biomedical Research Program. K.P. has received a fellowship from Fond de la recherche en santé Québec (FRSQ4729).

We thank Drs. Sara C. Kozma, Georges Thomas, and Matthias H. Tschöp for providing the S6KI1−/− mice. We are also grateful to Nancy Doughman for measuring plasma leucine levels and to Emily Matter and Joyce Sorrell for expert technical assistance.

Part of this study was presented in poster form at the 88th annual meeting of the Endocrine Society, Boston, Massachusetts, 24–27 June 2006.

REFERENCES

1. Benoit SC, Clegg DJ, Seeley RJ, Woods SC: Insulin and leptin as adiposity signals. Recent Prog Horm Res 56:257–285, 2001
2. Levin BE, Routh VH, Kang L, Sanders NM, Dunn-Meynell AA: Neuronal glucose sensing: what do we know after 50 years? Diabetes 53:2521–2528, 2004
3. Obici S, Rossetti L: Minireview: nutrient sensing and the regulation of insulin action and energy balance. Endocrinology 144:5172–5178, 2003
4. Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, Woods SC, Seeley RJ: Hypothalamic mTOR signaling regulates food intake. Science 312:927–930, 2006
5. Morrison CD, Xi X, White CL, Ye J, Martin RJ: Amino acids inhibit Agrp gene expression via an mTOR-dependent mechanism. Am J Physiol Endocrinol Metab 293:E165–E171, 2007
6. Cota D, Proulx K, Seeley RJ: The role of CNS fuel sensing in energy and glucose regulation. Gastroenterol 132:2158–2168, 2007
7. Pocai A, Lam TK, Obici S, Gutierrez-Juarez R, Maino ED, Ardashes A, Rossetti L: Restoration of hypothalamic lipid sensing normalizes energy and glucose homeostasis in overfed rats. J Clin Invest 116:1081–1091, 2006
8. He W, Lam TK, Obici S, Rossetti L: Molecular disruption of hypothalamic nutrient sensing induces obesity. Nat Neurosci 9:227–233, 2006
9. Hu Z, Dai Y, Prentki M, Choban S, Lane MD: A role for hypothalamic malonyl-CoA in the control of food intake. J Biol Chem 280:30681–30683, 2005
10. Lopez M, Lelliott CJ, Tovar S, Kimber W, Gallego R, Virtue S, Blount M, Vazquez MJ, Finer N, Powles TJ, O’Rahilly S, Saha AK, Dieguez C, Vidal-Puig AJ: Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA. Diabetes 55:1327–1336, 2006
11. Hu Z, Cha SH, Choban S, Lane MD: Hypothalamic malonyl-CoA as a mediator of feeding behavior. Proc Natl Acad Sci U S A 100:12624–12629, 2003
12. Clegg DJ, Wortman MD, Benoit SC, McOsker CC, Seeley RJ: Comparison of central and peripheral administration of C75 on food intake, body weight, and conditioned taste aversion. Diabetes 51:3106–3120, 2002
13. Wortman MD, Clegg DJ, D’Alessio D, Woods SC, Seeley RJ: C75 inhibits food intake by increasing CNS glucose metabolism. Nat Med 9:483–485, 2003
14. Lam TK, Schwartz GJ, Rossetti L: Hypothalamic sensing of fatty acids. Nat Neurosci 8:579–584, 2005
15. Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, Lane MD, Kuhajda FP: Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 288:2290–2290, 2000
16. Makimura H, Mizuno TM, Yang XJ, Silverstein J, Beasley J, Mobbs CV: Cerulein mimics effects of leptin on metabolic rate, food intake, and body weight independent of the melanocortin system, but unlike leptin, cerulein fails to block neuroendocrine effects of fasting. Diabetes 50:731–739, 2001

K. PROULX AND ASSOCIATES

DIABETES, VOL. 57, DECEMBER 2008
FAS INHIBITORS REGULATE CNS mTORC1

17. Kim EK, Miller I, Aja S, Landree LE, Pinn M, McFadden J, Kuhajda FP, Moran TH, Ronnett GV: C75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase. J Biol Chem 279:19070–19076, 2004

18. Gao S, Kinzig KP, Aja S, Scott KA, Keung W, Strynadka K, Chobman S, Smith WW, Tamashiro KL, Ladenheim EE, Ronnett GV, Tu Y, Birnbaum MJ, Lopaschuk GD, Moran TH: Leptin activates hypothalamic acetyl-CoA carboxylase to inhibit food intake. Proc Natl Acad Sci USA 104:17358–17363, 2007

19. Kosma SC, Thomas G: Regulation of cell size in growth, development and human disease. PEK1, PKB and S6K. Bioessays 24:65–71, 2002

20. Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes Dev 18:1926–1945, 2004

21. Bhaskar PT, Hay N: The two TORCs and Akt. Dev Cell 12:487–502, 2007

22. Reynolds TH, Bodine SC, Lawrence JC Jr: Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J Biol Chem 277:17657–17662, 2002

23. Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kosma SC: Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J 17:6649–6659, 1998

24. Chavez M, Kaiyala K, Madden LJ, Schwartz MW, Woods SC: Intraventricular insulin and the level of maintained body weight in rats. Behav Neurosci 109:528–531, 1995

25. Bjornsti MA, Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335–348, 2004

26. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, Thomas G: Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200–205, 2003

27. Kennedy AR, Pissios P, Otu H, Xue B, Asakura K, Furukawa N, Marino FE, Liu FF, Kahn BB, Libermann TA, Maratos-Flier E: A high-fat, ketogenic diet induces a unique metabolic state in mice. Am J Physiol Endocrinol Metab 292:E1724–E1739, 2007

28. Meijer AJ, Dubbelhuis PF: Amino acid signalling and the integration of metabolism. Biochim Biophys Acta 1753:387–403, 2004

29. Proud CG: Regulation of mammalian translation factors by nutrients. Eur J Biochem 269:5338–5349, 2002

30. Ronnett GV, Kleman AM, Kim EK, Landree LE, Tu Y: Fatty acid metabolism, the central nervous system, and feeding. Obesity 14 (Suppl. 5):2018–2078, 2006

31. Shimokawa T, Kumar MV, Lane MD: Effect of a fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides. Proc Natl Acad Sci USA 99:66–71, 2002

32. Yudkoff M, Daikhin Y, Nissim I, Lazarov A, Nissim I: Ketogenic diet, amino acid metabolism, and seizure control. J Neurosci Res 66:931–940, 2001

33. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, Foufelle F, Ferre P, Birnbaum MJ, Stuck BJ, Kahn BB: AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428:569–574, 2004

34. Inoki K, Zhu T, Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577–590, 2003

35. Aguilar V, Alliovacheva S, Sotiropoulos A, Sobering A, Athea Y, Djouadi F, Miraux S, Thiaudiere E, Foretz M, Viollet B, Diolez P, Benit P, Rustin P, Carlng D, Sandri M, Ventura-Clapier R, Pende M: S6 kinase deletion suppresses muscle growth adaptations to nutrient availability by activating AMP kinase. Cell Metab 5:476–487, 2007

36. Shu JW, Lindenberg DL, Mizuno TM, Roberts J, Mobbs CV: The fatty acid synthase inhibitor cerulenin and feeding, like leptin, activate hypothalamic pro-opiomelanocortin (POMC) neurons. Brain Res 985:1–12, 2003

37. Chakravarthy MV, Zhu Y, Lopez M, Yin L, Wozniak DF, Coleman T, Hu Z, Wolfgang M, Vidal-Puig A, Lane MD, Semenkovich CF: Brain fatty acid synthase activates PPARalpha to maintain energy homeostasis. J Clin Invest 117:2539–2552, 2007

38. Ronnett GV, Kim EK, Landree LE, Tu Y: Fatty acid metabolism as a target for obesity treatment. Physiol Behav 85:25–35, 2005

39. Kuhajda FP, Landree LE, Ronnett GV: The connections between C75 and obesity drug-target pathways. Trends Pharmacol Sci 26:541–544, 2005

40. Kim EK, Miller I, Landree LE, Birsoy-Rudin FF, Brown P, Tihan T, Townsend CA, Witters LA, Moran TH, Kuhajda FP, Ronnett GV: Expression of FAS within hypothalamic neurons: a model for decreased food intake after C75 treatment. Am J Physiol 283:E567–E579, 2002